North Point Portfolio Managers Corp OH Has $396,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

North Point Portfolio Managers Corp OH increased its position in Eli Lilly and Company (NYSE:LLYFree Report) by 29.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 679 shares of the company’s stock after purchasing an additional 154 shares during the quarter. North Point Portfolio Managers Corp OH’s holdings in Eli Lilly and Company were worth $396,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth $363,000. Liontrust Investment Partners LLP acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $8,326,000. WASHINGTON TRUST Co boosted its position in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the last quarter. Finally, Armstrong Fleming & Moore Inc acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $357,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of Eli Lilly and Company stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the completion of the transaction, the insider now owns 99,719,884 shares of the company’s stock, valued at approximately $63,004,019,910.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Up 1.8 %

Eli Lilly and Company stock traded up $13.96 during midday trading on Wednesday, reaching $777.92. The stock had a trading volume of 1,159,113 shares, compared to its average volume of 3,187,945. The stock has a market capitalization of $739.15 billion, a P/E ratio of 134.21, a price-to-earnings-growth ratio of 1.67 and a beta of 0.34. The firm’s fifty day simple moving average is $742.32 and its 200-day simple moving average is $642.33. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 1-year low of $351.27 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.09 earnings per share. As a group, analysts expect that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Monday. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $700.00.

View Our Latest Research Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.